|
Pegfilgrastim PBPC Mobilization Study Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Pegfilgrastim PBPC Mobilization Study conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Pegfilgrastim PBPC Mobilization Study Clinical research trials and Pegfilgrastim PBPC Mobilization Study medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Pegfilgrastim PBPC Mobilization Study. Pegfilgrastim PBPC Mobilization Study Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Pegfilgrastim PBPC Mobilization Study clinical trial. Participants frequently get the best healthcare available for their Pegfilgrastim PBPC Mobilization Study condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Pegfilgrastim PBPC Mobilization Study  Pegfilgrastim PBPC Mobilization Study
Pegfilgrastim PBPC Mobilization Study
For Condition: Lymphoma,Oncology,Lymphoma, Non-Hodgkin,Hodgkin Disease,Hematology
Status: No longer recruiting
Sponsor(s): Amgen ,
Synopsis: This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation in patients with Hodgkin's or non-Hodgkin's lymphoma.
Details: This is a research study for Hodgkin's Disease and Non-Hodgkin's Lymphoma (NHL) patients who will receive high-dose chemotherapy with autologous peripheral blood stem cell (PBSC or PBPC) transplant. The chemotherapy doses are high enough to severely suppress the bone marrow (where blood cells are made) and cause very low blood counts. A collection of stem cells (very young blood cells) followed by reinfusion to restore blood counts will be done to stimulate recovery of your blood counts. This procedure is called leukapheresis. Giving growth factors to patients is a method to increase the number of PBPC that can be collected during leukapheresis. This process of giving growth factors to patients is called mobilization (moving cells from the bone marrow to the peripheral blood where they can be collected). The purpose of this study is to determine if pegfilgrastim, an investigational drug, can safely and effectively mobilize stem cells. Filgrastim (also known as NEUPOGEN® or G-CSF) is approved by the FDA for stem cell mobilization. Pegfilgrastim is a modified version of Filgrastim that is longer acting.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Hodgkin's or non-Hodgkin's lymphoma patients suitable for an autologous PBPC transplant - No previous bone marrow or PBPC transplant
Total Enrollment:
Location and Contact Information:
Research Site
St. Louis, Missouri,
United States
Research Site
Philadelphia, Pennsylvania,
United States
Research Site
Maywood, Illinois,
United States
Research Site
New York City, New York,
United States
Research Site
Miami, Florida,
United States
Research Site
Los Angeles, California,
United States
Research Site
Detroit, Michigan,
United States
Research Site
Chapel Hill, North Carolina,
United States
Research Site
Duarte, California,
United States
Additional Information:
Study ID Numbers: 20020112;
Study Start Date: November 2002
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00066092
Other Lymphoma, Non-Hodgkin Studies:
1. Evaluation and Natural History of Children with Cancer and AIDS
2. Donor Stem Cell Transplantation in Treating Patients With Relapsed Hematologic Cancer
3. Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy
4. Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
5. LMP2a-Specific Cytotoxic T-Lymphocytes Following CD45 Antibody for Lymphoma
Related Studies:
Other Lymphoma, Non-Hodgkin Clinical Trials
Other Illinois Clinical Trials
Other Maywood Clinical Trials
Pegfilgrastim PBPC Mobilization Study
|
|
|
|
|
|
|
|
